Process Validationprotocol and Report
Process Validationprotocol and Report
REPORT No.:
Effective Date:
GMH/PVR/L05/23/01
Levocetirizine Tablets IP
Revision No.: 01 Review Date:
Supersedes: 00 Page No. : 1 of 18
VERSION No.: 01
EFFECTIVE DATE:
REPORT No.:
Effective Date:
GMH/PVR/L05/23/01
Levocetirizine Tablets IP
Revision No.: 01 Review Date:
Supersedes: 00 Page No. : 2 of 18
TABLE OF CONTENTS
S. No. Page Nos.
TABLE OF CONTENTS
Cover Page 01 of 27
Table of contents 02 of 27
REPORT No.:
Effective Date:
GMH/PVR/L05/23/01
Levocetirizine Tablets IP
Revision No.: 01 Review Date:
Supersedes: 00 Page No. : 3 of 18
Description: White colored round shaped biconvex having plain on both side Film coated tablet.
REPORT No.:
Effective Date:
GMH/PVR/L05/23/01
Levocetirizine Tablets IP
Revision No.: 01 Review Date:
Supersedes: 00 Page No. : 4 of 18
The quantity of various ingredients required for the manufacturing of the batch is detailed below.
SR.No Material Name Spec. Function Qty. Per Qty. For
. Tablet 1,00,000
(mg) (kg)
1. MCC Plain IP Binder 50.00 5.000
REPORT No.:
Effective Date:
GMH/PVR/L05/23/01
Levocetirizine Tablets IP
Revision No.: 01 Review Date:
Supersedes: 00 Page No. : 5 of 18
REPORT No.:
Effective Date:
GMH/PVR/L05/23/01
Levocetirizine Tablets IP
Revision No.: 01 Review Date:
Supersedes: 00 Page No. : 6 of 18
as follows:
REPORT No.:
Effective Date:
GMH/PVR/L05/23/01
Levocetirizine Tablets IP
Revision No.: 01 Review Date:
Supersedes: 00 Page No. : 7 of 18
3.
REPORT No.:
Effective Date:
GMH/PVR/L05/23/01
Levocetirizine Tablets IP
Revision No.: 01 Review Date:
Supersedes: 00 Page No. : 8 of 18
Particulars Observations
Date: Date: Date:
Sieve size80 #,#40, (mesh) B.No. B.No. B.No.
Levocetirizine
MCC Plain
D.C.P
Maize Starch
MCC-102 (DC Grade)
Crosspovidone XL-10
Crosscarmellose Sodium
Sodium Lauryal Sulphate
Colloidal Silicon Dioxide
Talcum
Format No.: QA-030/ A02/00
GMH LABORATORIES
Plot No.-13, Industrial Township, Bhatoli Kalan , Baddi Distt.-Solan
(H.P.) 173205
REPORT No.:
Effective Date:
GMH/PVR/L05/23/01
Levocetirizine Tablets IP
Revision No.: 01 Review Date:
Supersedes: 00 Page No. : 9 of 18
Magnesium Stearate
M.C.C -102(Excess)
6.2 CONCLUSION:
After sifting from .................. found to be within the acceptable limits hence it is concluded that
………...…. is the validated sieve for sifting
REPORT No.:
Effective Date:
GMH/PVR/L05/23/01
Levocetirizine Tablets IP
Revision No.: 01 Review Date:
Supersedes: 00 Page No. : 10 of 18
6.3 LUBRICATION:-
During this stage granules are mixed with a lubricant, which is influencing the flow pattern and
content uniformity of the blend for compression of Tablets.
Shift the Lubrication material and add to the blender
Lubrication:
Date(....................) Batch No. :-(....................................)
Material Name Levocetirizine Flow Property
(Assay)%
RT
CT
LT
FT
BT
After 15 Minutes RM
LM
CM
LB
RB
Comp.
RT
CT
LT
FT
BT
After 30 Minutes RM
LM
CM
LB
RB
Comp.
After 60 Minutes RT
CT
LT
REPORT No.:
Effective Date:
GMH/PVR/L05/23/01
Levocetirizine Tablets IP
Revision No.: 01 Review Date:
Supersedes: 00 Page No. : 11 of 18
FT
BT
RM
LM
CM
LB
RB
Comp.
REPORT No.:
Effective Date:
GMH/PVR/L05/23/01
Levocetirizine Tablets IP
Revision No.: 01 Review Date:
Supersedes: 00 Page No. : 12 of 18
BT
RM
LM
CM
LB
RB
Comp.
Date :(......................) Batch No. :-(...............................)
Material Name Levocetirizine Aceclofenac
(Assay)% (Assay %)
RT
CT
LT
FT
BT
After 15 Minutes RM
LM
CM
LB
RB
Comp.
RT
CT
LT
FT
BT
After 30 Minutes RM
LM
CM
LB
RB
Comp.
After 60 Minutes RT
CT
LT
FT
BT
RM
Format No.: QA-030/ A02/00
GMH LABORATORIES
Plot No.-13, Industrial Township, Bhatoli Kalan , Baddi Distt.-Solan
(H.P.) 173205
REPORT No.:
Effective Date:
GMH/PVR/L05/23/01
Levocetirizine Tablets IP
Revision No.: 01 Review Date:
Supersedes: 00 Page No. : 13 of 18
LM
CM
LB
RB
Comp.
VISUAL INSPECTION: Visual inspection helps to remove the physical defects of the tablets,
thus ensure appearance quality of tablets.
Take the line clearance from IPQA for Area and machines/equipment’s cleanliness and for
unwanted materials. Record the Temperature NMT 25±2 °C and Relative humidity NMT 55 ± 5
% of the Inspection Area
Sr. No. Physical Defects/Rejections
1. Appearance 5. Erosion
2. Picking and Sticking 6. Bridging
3. Capping 7. Cracking
4. Chipping
Load the tablets in the visual inspection table and observe the tablets for the defects and remove
the defects.
PACKING:
Run the machine at different speed and the Different Forming & Sealing temperature.
REPORT No.:
Effective Date:
GMH/PVR/L05/23/01
Levocetirizine Tablets IP
Revision No.: 01 Review Date:
Supersedes: 00 Page No. : 14 of 18
130 170
30 Forming Temp Sealing
150 210
40 Forming Temp Sealing
120 Temp 150
40 Forming Temp Sealing
130 170
40 Forming Temp Sealing
150 210
Physical Verification, at Minimum Speed and Maximum Sealing Temperature.
REPORT No.:
Effective Date:
GMH/PVR/L05/23/01
Levocetirizine Tablets IP
Revision No.: 01 Review Date:
Supersedes: 00 Page No. : 15 of 18
Run the machine at different speed and the Different Forming & Sealing temperature.
REPORT No.:
Effective Date:
GMH/PVR/L05/23/01
Levocetirizine Tablets IP
Revision No.: 01 Review Date:
Supersedes: 00 Page No. : 16 of 18
6. Width Limit-8.20 mm ±
0.02% mm
7. Thickness Limit-5.50 mm ±
0.02% mm
8. Hardness NLT-4.0kg/cm2
9. Friability NMT-1.0%ww
10. Disintegration Time NMT-15.0Minutes
11. Assay: each film coated tablet Limit-90.00 mg to
contains- 110.0 mg
Aceclofenac 100 mg (NLT-90.0% & NMT-
110.0%)
RESULTS EVALUATION:-
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
_____________________________________________________________________
DEVIATION:-
______________________________________________________________________________
REPORT No.:
Effective Date:
GMH/PVR/L05/23/01
Levocetirizine Tablets IP
Revision No.: 01 Review Date:
Supersedes: 00 Page No. : 17 of 18
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
STABILITY:-
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
ABBREVIATIONS:-
REPORT No.:
Effective Date:
GMH/PVR/L05/23/01
Levocetirizine Tablets IP
Revision No.: 01 Review Date:
Supersedes: 00 Page No. : 18 of 18